Yet, other studies indicate that activation of the PI-3K/Akt signaling confers resistance to trastuzumab, but not lapatinib [21, 22], and lapatinib potently suppresses tumor growth of HER2-positive BC in a PTEN-independent manner [23]. The gene discussed is ERBB2; the disease is breast cancer.